(Q42684792)

4 November 2017

title

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease (English)

1 reference

4 November 2017

1 reference

7

1 reference

4 November 2017

T J Creed

1

1 reference

4 November 2017

C S J Probert

2

1 reference

4 November 2017

M N Norman

3

1 reference

4 November 2017

M Moorghen

4

1 reference

4 November 2017

N A Shepherd

5

1 reference

4 November 2017

S D Hearing

6

1 reference

4 November 2017

BASBUC INVESTIGATORS

8

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Alimentary Pharmacology & Therapeutics

4 November 2017

published in

1 reference

4 November 2017

volume

23

1 reference

4 November 2017

issue

10

1 reference

4 November 2017

page(s)

1435-1442

1 reference

Lieberkühn of the crypts of Lieberkühn

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Glucocorticoid resistance - what is known?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Intensive intravenous regimen for severe attacks of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

A benefit-risk assessment of basiliximab in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02904.X

10.1111/J.1365-2036.2006.02904.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference